Jefferies Downgrades Aegerion Pharmaceuticals To Hold

Analysts at Jefferies downgraded Aegerion Pharmaceuticals AEGR from Buy to Hold. The price target for Aegerion Pharmaceuticals has been lowered from $61.00 to $24.00. Aegerion Pharmaceuticals shares have dropped 58.68% over the past 52 weeks, while the S&P 500 index has surged 13.56% in the same period. Aegerion Pharmaceuticals' shares fell 31.28% to $23.51 in pre-market trading.